Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals | Small Cap
Health Score : 4.22Biofil Chemicals & Pharmaceuticals Ltd operates within the Pharmaceuticals & Biotechnology sector. The company exhibits strengths in solvency and growth, driven by low debt levels and robust revenue and asset expansion. However, profitability metrics, such as gross profit margin, return on capital employed, return on equity and return on assets needs improvement. Efficiency ratios also indicate potential challenges in managing inventory and receivables. While the company's coverage ratios are strong, financial ratios suggest concerns with earnings per share and book value. The company demonstrates good revenue growth and management of its assets, but struggles in converting sales into profit and also needs to enhance profitability and efficiency to ensure sustainable financial health.
Health Score : 4.22Biofil Chemicals & Pharmaceuticals Ltd operates within the Pharmaceuticals & Biotechnology sector. The company exhibits strengths in solvency and growth, driven by low debt levels and robust revenue and asset expansion. However, profitability metrics, such as gross profit margin, return on capital employed, return on equity and return on assets needs improvement. Efficiency ratios also indicate potential challenges in managing inventory and receivables. While the company's coverage ratios are strong, financial ratios suggest concerns with earnings per share and book value. The company demonstrates good revenue growth and management of its assets, but struggles in converting sales into profit and also needs to enhance profitability and efficiency to ensure sustainable financial health.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
19.61
Industry Median
19.41
Small Cap Median
18.08
P/E RATIO
100.94
P/B RATIO
2.62
Industry Median
1.98
Small Cap Median
2.03
P/S RATIO
N/A
Industry Median
2.06
Small Cap Median
1.64
Others
PEG RATIO
-7.06
EV/EBITDA RATIO
48.23
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹34.32 as on Feb 20, 2026.
Growth Score : 5.30The company has mixed performance in growth metrics. Strong revenue and asset growth rates indicate good expansion. However, declines in operating profit and EPS growth suggest that profitability is not keeping pace with revenue. This could be due to rising costs or reduced efficiency. While the company is expanding, it needs to focus on improving profitability to ensure sustainable growth. However, high asset growth might be due to strategic investments in R&D or infrastructure, which could yield long-term benefits.
Revenue Growth RateExcellentOperating Profit Growth RatePoorEarnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RateWeak| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -37.4 | 34.23 | 33.29 | -16.58 | -14.97 |
| Operating Profit Growth Rate | -16.88 | -12.78 | -30.17 | 4.94 | -23.53 |
| Earnings Per Share (EPS) Growth | -43.42 | -20.93 | 29.41 | -22.73 | 402.94 |
| Asset Growth Rate | -43.65 | 67.65 | 49.94 | 8.22 | -15.9 |
| Net Income Growth Rate | -43.55 | -20 | 26.79 | -21.13 | 398.21 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Biofil Chemicals & Pharmaceuticals Ltd | 4.22 | 100.94 | Neutral | 0.78 | 0.30 | 0.48 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Biofil Chemicals & Pharmaceuticals Ltd is an Indian pharmaceutical company primarily engaged in the manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and drug intermediates. It caters to both domestic and international markets, focusing on quality and cost-effectiveness in its product portfolio, with a significant presence in anti-infective segments.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Biofil Chemicals & Pharmaceuticals Ltd's P/E ratio (TTM) is 19.61, compared to the industry median of 19.41 and large cap median of 18.08.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Biofil Chemicals & Pharmaceuticals Ltd's P/B ratio is 2.62, compared to the industry median of 1.98 and large cap median of 2.03.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Biofil Chemicals & Pharmaceuticals Ltd's P/S ratio is 1.14, compared to the industry median of 2.06 and large cap median of 1.64.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Biofil Chemicals & Pharmaceuticals Ltd's PEG ratio is -7.06.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Biofil Chemicals & Pharmaceuticals Ltd's EV/EBITDA ratio is 48.23.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Biofil Chemicals & Pharmaceuticals Ltd's ROE is 12.94%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Biofil Chemicals & Pharmaceuticals Ltd's ROA is 1.52%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Biofil Chemicals & Pharmaceuticals Ltd's ROCE is 15.79%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Biofil Chemicals & Pharmaceuticals Ltd's operating margin is 2.29%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Biofil Chemicals & Pharmaceuticals Ltd's net margin is 9.82%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Biofil Chemicals & Pharmaceuticals Ltd's current ratio is 1.69.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Biofil Chemicals & Pharmaceuticals Ltd's debt-to-equity ratio is 0.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Biofil Chemicals & Pharmaceuticals Ltd's interest coverage ratio is 346.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Biofil Chemicals & Pharmaceuticals Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Biofil Chemicals & Pharmaceuticals Ltd's EPS is 402.94.
(Source line: "Ratios as of 23 Oct 2026, based on last traded price of ₹34.32. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1985
Headquarters: Indore, Madhya Pradesh
Core Offerings: Active Pharmaceutical Ingredients (APIs), Drug Intermediates, Bulk Drugs, Metronidazole Benzoate, Tinidazole
Stock Listing: NSE (BIOFILCHEM), BSE (524396)
Promoter: S. L. Agarwal & family
Founded in 1985, Biofil Chemicals & Pharmaceuticals Ltd commenced operations with a focus on manufacturing bulk drugs and drug intermediates. Over the decades, it has steadily expanded its portfolio of Active Pharmaceutical Ingredients (APIs), establishing itself as a recognized player in the pharmaceutical sector, serving both domestic and international clients, primarily from its Indore facilities.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Active Pharmaceutical Ingredients (APIs) & Intermediates | 100% | Operating Profit |
Active Pharmaceutical Ingredients (APIs) & Intermediates: Specializes in the production of various bulk drugs, including Metronidazole Benzoate, Tinidazole, Ornidazole, and Secnidazole, which are critical components for pharmaceutical formulations.
Manufacturing Facilities: Operates modern, quality-compliant manufacturing units in Indore, Madhya Pradesh, adhering to national and international pharmaceutical standards.
Mr. Surendra Kumar Singhvi - Chairman & Managing Director. He brings extensive experience in the pharmaceutical industry, guiding the company's strategic direction and operational excellence.
No major subsidiaries reported.
1:1 Bonus Issue declared in November 2021.
The Biofil Chemicals & Pharmaceuticals Ltd share price today is ₹34.32 on NSE (BIOFILCHEM), as of 23 Oct 2026.
As of 23 Oct 2026, Biofil Chemicals & Pharmaceuticals Ltd share price is ₹34.32, with previous close ₹34.32. Today's range is ₹34.32 to ₹34.32. The 52-week range is ₹25.60 to ₹46.34.
As of today, Biofil Chemicals & Pharmaceuticals Ltd's market cap is ₹55.94 crore (Small Cap).
Biofil Chemicals & Pharmaceuticals Ltd's current P/E ratio is 19.61, compared to the Pharmaceuticals & Biotechnology sector average of 33.50.
Biofil Chemicals & Pharmaceuticals Ltd's current P/B ratio is 2.62.
Biofil Chemicals & Pharmaceuticals Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Biofil Chemicals & Pharmaceuticals Ltd's EPS (TTM) is ₹402.94.
Biofil Chemicals & Pharmaceuticals Ltd is an Indian pharmaceutical company primarily engaged in the manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and drug intermediates. It caters to both domestic and international markets, focusing on quality and cost-effectiveness in its product portfolio, with a significant presence in anti-infective segments.
Biofil Chemicals & Pharmaceuticals Ltd is promoted by S. L. Agarwal & family, holding 46.79% as of 23 Oct 2026.
Biofil Chemicals & Pharmaceuticals Ltd is listed on NSE (BIOFILCHEM) and BSE (524396). Its next quarterly results are expected on August 2024.
